Switch theme
Sign up to access all valuation multiples
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
1996
3.0K+
LTM Revenue $3.0B
LTM EBITDA $734M
$10.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biomarin Pharmaceutical has a last 12-month revenue (LTM) of $3.0B and a last 12-month EBITDA of $734M.
In the most recent fiscal year, Biomarin Pharmaceutical achieved revenue of $2.9B and an EBITDA of $651M.
Biomarin Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biomarin Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | XXX | $2.9B | XXX | XXX | XXX |
| Gross Profit | $2.4B | XXX | $2.3B | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $734M | XXX | $651M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $626M | XXX | $474M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $538M | XXX | $427M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biomarin Pharmaceutical's stock price is $58.
Biomarin Pharmaceutical has current market cap of $11.1B, and EV of $10.5B.
See Biomarin Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.5B | $11.1B | XXX | XXX | XXX | XXX | $2.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biomarin Pharmaceutical has market cap of $11.1B and EV of $10.5B.
Biomarin Pharmaceutical's trades at 3.7x EV/Revenue multiple, and 16.1x EV/EBITDA.
Equity research analysts estimate Biomarin Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biomarin Pharmaceutical has a P/E ratio of 20.7x.
See valuation multiples for Biomarin Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11.1B | XXX | $11.1B | XXX | XXX | XXX |
| EV (current) | $10.5B | XXX | $10.5B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 14.3x | XXX | 16.1x | XXX | XXX | XXX |
| EV/EBIT | 16.7x | XXX | 22.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.7x | XXX | 26.1x | XXX | XXX | XXX |
| EV/FCF | 17.2x | XXX | 22.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiomarin Pharmaceutical's last 12 month revenue growth is 10%
Biomarin Pharmaceutical's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.6M for the same period.
Biomarin Pharmaceutical's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biomarin Pharmaceutical's rule of X is 50% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biomarin Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | 73% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomarin Pharmaceutical acquired XXX companies to date.
Last acquisition by Biomarin Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Biomarin Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biomarin Pharmaceutical founded? | Biomarin Pharmaceutical was founded in 1996. |
| Where is Biomarin Pharmaceutical headquartered? | Biomarin Pharmaceutical is headquartered in United States of America. |
| How many employees does Biomarin Pharmaceutical have? | As of today, Biomarin Pharmaceutical has 3.0K+ employees. |
| Who is the CEO of Biomarin Pharmaceutical? | Biomarin Pharmaceutical's CEO is Mr. Alexander Hardy. |
| Is Biomarin Pharmaceutical publicy listed? | Yes, Biomarin Pharmaceutical is a public company listed on NAS. |
| What is the stock symbol of Biomarin Pharmaceutical? | Biomarin Pharmaceutical trades under BMRN ticker. |
| When did Biomarin Pharmaceutical go public? | Biomarin Pharmaceutical went public in 1999. |
| Who are competitors of Biomarin Pharmaceutical? | Similar companies to Biomarin Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biomarin Pharmaceutical? | Biomarin Pharmaceutical's current market cap is $11.1B |
| What is the current revenue of Biomarin Pharmaceutical? | Biomarin Pharmaceutical's last 12 months revenue is $3.0B. |
| What is the current revenue growth of Biomarin Pharmaceutical? | Biomarin Pharmaceutical revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Biomarin Pharmaceutical? | Current revenue multiple of Biomarin Pharmaceutical is 3.5x. |
| Is Biomarin Pharmaceutical profitable? | Yes, Biomarin Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biomarin Pharmaceutical? | Biomarin Pharmaceutical's last 12 months EBITDA is $734M. |
| What is Biomarin Pharmaceutical's EBITDA margin? | Biomarin Pharmaceutical's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Biomarin Pharmaceutical? | Current EBITDA multiple of Biomarin Pharmaceutical is 14.3x. |
| What is the current FCF of Biomarin Pharmaceutical? | Biomarin Pharmaceutical's last 12 months FCF is $610M. |
| What is Biomarin Pharmaceutical's FCF margin? | Biomarin Pharmaceutical's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Biomarin Pharmaceutical? | Current FCF multiple of Biomarin Pharmaceutical is 17.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
